- Significant bioavailability results were reported from LXRP’s randomized, double-blind European study that evaluated its proprietary TurboCBD capsules, powered by DehydraTECH
- Results corroborate and confirm in vitro and in vivo studies of DehydraTECH technology that measured high levels of drug delivery being achieved faster than with matching controls
- LXRP says that it is pleased that DehydraTECH has, to date, repeatedly proved evidence of success within human studies; technology earlier demonstrated ability to deliver nicotine
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is pleased to report significant bioavailability results from its randomized and double-blind European human clinical study of DehydraTECH™ powered TurboCBD™ and cannabidiol (CBD) fortified hemp oil capsules (http://ibn.fm/rPBS5). The new study evaluated the speed and degree of CBD absorption into blood plasma and included cardiovascular and cognitive enhancement in male volunteers.
Results corroborate and confirm earlier in vitro and in vivo studies that evaluated DehydraTECH’s platform and measured higher levels of drug delivery achieved quicker than controls with matching CBD amounts. LXRP said that it believes nearly identical bioavailability enhancement results would be shown if the cannabinoid was THC instead of CBD.
Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology to promote healthier ingestion methods. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio. DehydraTECH is its proprietary absorption technology platform.
In the six hours of the latest study, LXRP’s TurboCBD capsules delivered more CBD to the blood than the positive control capsules at each time point in the study up to its completion.
According to an article published by CFN Media Group, LXRP has applied for a patent to the USPTO, because, in lab studies, the proprietary technology may have proved itself capable of transporting active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier (http://ibn.fm/jhx1Z).
That barrier blocks blood-borne circulating toxins and is a challenge to researchers trying to deliver APIs in medications. The barrier serves as a significant hindrance for drug treatment of diseases of the central nervous system. In lab tests, DehydraTECH was able to transport more nicotine to the brain tissue, conjugating or joining with APIs for maximum delivery.
LXRP has been conducting in vivo lab studies on animals to, in part, determine DehydraTECH’s ability to deliver enhanced levels of nicotine to the bloodstream and brain tissue. The studies found that this platform was able to deliver up to 560 percent greater amounts of nicotine to the brain tissue compared to controls without DehydraTECH. Originally, the tests were focused on developing products for nicotine replacement (http://ibn.fm/PJVMI).
These studies demonstrated that the DehydraTECH platform could effectively transport drugs, in this case nicotine, across the blood brain barrier. As a result, LXRP filed for a patent for DehydraTECH’s innovative treatment options for diseases and disorders including Alzheimer’s, Huntington’s and Parkinson’s. LXRP hopes to leverage this future possible patent to commercialize its development of future new products that treat central nervous system diseases.
For more information, visit the company’s website at www.LexariaBioscience.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php